1. Which of the following is NOT part of the new standard of care for HCV treatment for 2015 based on the VA guidelines?

2. JP is a 28-year-old man infected with HCV genotype 1. His current HCV RNA is higher than 6 million and he is treatment naive. He is noncirrhotic and not infected with HIV and is currently taking duloxetine 60 mg/day for mild depression. He has no other comorbidities and is HCV treatment-naïve. Which of the following would be the recommended treatment duration for JP when starting on sofosbuvir plus ledipasvir therapy?

3. Which of the following would NOT affect treatment choice or duration when choosing an HCV antiviral regiment?

4. LB is a 37-year-old woman who has been HCV positive for 6 years. She is a single mother of 4 who works 2 part-time jobs. She is a smoker (1 pack-per-day) and former intravenous drug user, having abstained from recreational drug use for the past 3 years. Her liver biopsy is inconclusive for cirrhosis. Her HCV treatment history includes P/R, which resulted in a low response rate, and the addition of telaprevir, which was taken only intermittently and ultimately discontinued due to severe skin reaction. Her primary care physician is considering an interferon-free regimen for LB's HCV. Which of the following would be the MOST effective strategy to increase her chances of successful treatment?

« Return to Activity